Viral protein Nef enables a step toward off-the-shelf CAR T cell therapy for cancer
CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...
GEN1d
Making Strides Toward Off-the-Shelf CAR T Cell Therapy for Cancer
A new advance may make it possible to use off-the-shelf CAR T cells provided by healthy donors. The new approach studied in mice equipped CAR T cells with the viral protein Nef.
Targeted Oncology12d
First Dose of CD38-Targeting CAR T-Cell Therapy Administered in AML
The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...
VectorBuilder Powers FDA IND Approval of World’s First Umbilical Cord Blood-Derived Allogeneic CAR-T Product
VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ...
Health Rounds: Old anti-inflammatory may delay colon cancer recurrence
Patients with colon cancer who still have cancer cells in their blood after surgery may improve their survival odds with ...
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune Disease Indications; Inno ...
GEN22h
Cancer Immunotherapy: From Nineteenth-Century Beginnings to Modern Breakthroughs
Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...
FiercePharma13d
Atara's Ebvallo and pipeline candidate put on clinical hold in US after partner's failed plant inspection
After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...
Targeted Oncology5d
FDA Grants Orphan Drug Designation to MB-105 for R/R T-Cell Lymphoma
MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...
BioSpace4d
Cargo Halts CAR T Trial, Lays Off 50% of Workforce in Pipeline Reset
CAR T–focused biotech Cargo Therapeutics surprised and disappointed analysts when it announced that it would discontinue a ...
Morningstar6d
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Dual-Targeted CD19/CD70 Allogeneic CAR T ... which leverages the clinically validated Dagger® technology to drive CAR T cell expansion and prevent rejection, includes two distinct lymphodepletion ...